| Schedule of Quarterly Financial Data |
Quarterly financial information for fiscal 2015 and 2014 are presented in the following table, in thousands, except per share data:
|
|
|
For the Quarter Ending
|
|
|
|
|
March 31
|
|
|
June 30
|
|
|
September 30
|
|
|
December 31
|
|
|
2015:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Lymphoseek sales revenue
|
|
$
|
1,835
|
|
|
$
|
1,964
|
|
|
$
|
2,953
|
|
|
$
|
3,503
|
|
|
Lymphoseek license revenue
|
|
|
83
|
|
|
|
250
|
|
|
|
550
|
|
|
|
250
|
|
|
Grant and other revenue
|
|
|
190
|
|
|
|
654
|
|
|
|
477
|
|
|
|
541
|
|
|
Gross profit
|
|
|
1,659
|
|
|
|
2,535
|
|
|
|
3,522
|
|
|
|
3,778
|
|
|
Operating expenses
|
|
|
9,475
|
|
|
|
6,346
|
|
|
|
7,845
|
|
|
|
6,379
|
|
|
Operating loss
|
|
|
(7,816
|
)
|
|
|
(3,811
|
)
|
|
|
(4,323
|
)
|
|
|
(2,601
|
)
|
|
Net loss attributable to common stockholders
|
|
|
(7,337
|
)
|
|
|
(9,691
|
)
|
|
|
(8,071
|
)
|
|
|
(2,510
|
)
|
|
Basic and diluted net loss per share (1)
|
|
$
|
(0.05
|
)
|
|
$
|
(0.06
|
)
|
|
$
|
(0.05
|
)
|
|
$
|
(0.02
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2014:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Lymphoseek sales revenue
|
|
$
|
627
|
|
|
$
|
1,046
|
|
|
$
|
1,101
|
|
|
$
|
1,460
|
|
|
Lymphoseek license revenue
|
|
|
—
|
|
|
|
—
|
|
|
|
300
|
|
|
|
—
|
|
|
Grant and other revenue
|
|
|
125
|
|
|
|
28
|
|
|
|
849
|
|
|
|
738
|
|
|
Gross profit
|
|
|
559
|
|
|
|
804
|
|
|
|
1,442
|
|
|
|
1,884
|
|
|
Operating expenses
|
|
|
9,138
|
|
|
|
10,020
|
|
|
|
6,805
|
|
|
|
6,360
|
|
|
Operating loss
|
|
|
(8,579
|
)
|
|
|
(9,216
|
)
|
|
|
(5,363
|
)
|
|
|
(4,476
|
)
|
|
Net loss attributable to common stockholders
|
|
|
(11,741
|
)
|
|
|
(10,222
|
)
|
|
|
(6,899
|
)
|
|
|
(6,865
|
)
|
|
Basic and diluted net loss per share (1)
|
|
$
|
(0.08
|
)
|
|
$
|
(0.07
|
)
|
|
$
|
(0.05
|
)
|
|
$
|
(0.05
|
)
|
|
|
(1)
|
Net loss per share is computed independently for each of the quarters presented. Therefore the sum of the quarterly per-share calculations will not necessarily equal the annual per share calculation.
|
|